Jan-Quinten Mol, MD; Rick H. J. A. Volleberg, MD; Anouar Belkacemi, MD, PhD; et al.
JAMA Cardiol. 2023;8(11):1013-1021. doi:10.1001/jamacardio.2023.2910
This cohort study assesses the association between optical coherence tomography (OCT)-detected, fractional flow reserve (FFR)-negative nonculprit lesions and adverse cardiovascular events in patients with myocardial infarction (MI).
Harman Yonis, MD; Kathrine Kold Sørensen, MScPH; Henrik Bøggild, MD, PhD; et al.
JAMA Cardiol. 2023;8(11):1022-1030. doi:10.1001/jamacardio.2023.2934
This survey study uses standardized patient-reported outcome measures to determine the long-term quality of life of survivors of out-of-hospital cardiac arrest in Denmark.
Jean-Luc Balligand, MD; Dulce Brito, MD; Oana Brosteanu, PhD; et al.
open access
JAMA Cardiol. 2023;8(11):1031-1040. doi:10.1001/jamacardio.2023.3003
This randomized clinical trial evaluates repurposing mirabegron, a β3-adrenergic receptor agonist, to prevent progression of left ventricular hypertrophy and diastolic dysfunction among patients with pre- or mild heart failure.
Ankeet S. Bhatt, MD, MBA, ScM; Muthiah Vaduganathan, MD, MPH; Brian L. Claggett, PhD; et al.
JAMA Cardiol. 2023;8(11):1041-1048. doi:10.1001/jamacardio.2023.3216
This economic evaluation examines the cost-effectiveness of sacubitril-valsartan among a range of ejection fractions and at different upper-level cutoffs of below-normal ejection fractions.
-
Invited Commentary
Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions
Laura P. Cohen, MD, MPP; Brandon K. Bellows, PharmD, MS
JAMA Cardiol
John W. Ostrominski, MD; Suzanne V. Arnold, MD, MHA; Javed Butler, MD, MPH, MBA; et al.
has audio
JAMA Cardiol. 2023;8(11):1050-1060. doi:10.1001/jamacardio.2023.3241
This cohort study investigates the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, using data from the National Health and Nutrition Examination Survey.
-
Audio:
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
Amber Sleem, DO; Mark B. Effron, MD; Amanda Stebbins, MS; et al.
open access
JAMA Cardiol. 2023;8(11):1061-1069. doi:10.1001/jamacardio.2023.3364
This post hoc secondary analysis of a randomized clinical trial compares the effectiveness and safety of enteric-coated aspirin vs uncoated aspirin among patients with atherosclerotic cardiovascular disease.